ALDX News and Press, Aldeyra Therapeutics Inc. From 12/14/23

IMV Inc. (IMVIQ) is expected to report for Q3 2023 Orbit International Corp. (ORBT) is expected to report for quarter end 2023-09-30 PLx Pharma Winddown Corp. (PLXPQ) is expected to report for quarter end 2023-09-30 Advantage Energy Ltd (AAVVF) is expected to report for Q1 2024 We...

lululemon athletica inc. (LULU) is expected to report $2.27 for Q3 2024 Arco Platform Limited (ARCE) is expected to report $-0.17 for Q3 2023 Elekta AB ADR (EKTAY) is expected to report for Q2 2024 Kimberly - Clark de Mexico S.A. ADR (KCDMY) is expected to report for Q1 2024 Torri...

2023-12-05 09:11:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. Thes...

Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...

2023-11-27 17:12:15 ET More on Aldeyra Therapeutics Why I Am Selling Aldeyra Therapeutics: A Sour AbbVie Deal And A Lack Of Transparency Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash Eyeing Returns: Aldeyra's Shift From Lab To Market AbbVie e...

2023-11-27 17:02:48 ET More on Aldeyra Therapeutics Why I Am Selling Aldeyra Therapeutics: A Sour AbbVie Deal And A Lack Of Transparency Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash Eyeing Returns: Aldeyra's Shift From Lab To Market AbbVie e...

Additional Trial Required to Demonstrate Positive Effect on the Treatment of Ocular Symptoms in Dry Eye Disease Special Protocol Assessment Submitted on November 16, 2023 for Dry Eye Disease Chamber Crossover Clinical Trial Proposed Trial Top-Line Results and Potential NDA Resubmi...

Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...

thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...

2023-11-09 09:04:59 ET Summary Aldeyra Therapeutics is a strong sell as bearish developments have been met with silence from the management team, amplifying the uncertainty surrounding the future. The company is facing challenges in its journey to become a commercial biotech compa...